These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 18474663

  • 1. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
    Kain T, MacGregor D, Buchanan RR, de Jager JP, Schachna L.
    Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
    [No Abstract] [Full Text] [Related]

  • 2. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
    Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H.
    Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
    [No Abstract] [Full Text] [Related]

  • 3. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
    Montagna GL, Malesci D, Buono R, Valentini G.
    Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
    [No Abstract] [Full Text] [Related]

  • 4. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S.
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract] [Full Text] [Related]

  • 5. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
    Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P, BSR Standards, Guidelines and Audit Working group.
    Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
    [No Abstract] [Full Text] [Related]

  • 6. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
    Capkin E, Karkucak M, Yayli S, Aydin Çapkin A, Tosun M.
    J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
    [No Abstract] [Full Text] [Related]

  • 7. Localized Cutaneous Leishmaniasis due to Leishmania infantum in a Patient Treated with Infliximab.
    Hakimi S, Rivière S, Del Giudice P, Dereure J, Le Quellec A.
    Dermatology; 2010 Aug; 220(1):63-5. PubMed ID: 19907139
    [Abstract] [Full Text] [Related]

  • 8. Tuberculous peritonitis.
    Finlay DG, Szauter K, Raju GS, Snyder N.
    Am J Gastroenterol; 2005 Jul; 100(7):1624-5. PubMed ID: 15984997
    [No Abstract] [Full Text] [Related]

  • 9. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
    de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE.
    Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
    [No Abstract] [Full Text] [Related]

  • 10. Relapsing polychondritis: a new adverse event secondary to the use of tumour necrosis factor antagonists?
    Hernández MV, Ruiz-Esquide V, Gómez-Caballero ME, Gómez-Puerta JA, Cañete JD, Sanmartí R.
    Rheumatology (Oxford); 2011 Aug; 50(8):1523-5. PubMed ID: 21593064
    [No Abstract] [Full Text] [Related]

  • 11. Cardiopulmonary arrest after severe anaphylactic reaction to second infusion of infliximab in a patient with ankylosing spondylitis.
    Miki H, Okamoto A, Ishigaki K, Sasaki O, Sumitomo S, Fujio K, Yamamoto K.
    J Rheumatol; 2011 Jun; 38(6):1220. PubMed ID: 21632692
    [No Abstract] [Full Text] [Related]

  • 12. Do TNF-blockers reduce or induce uveitis?
    Cobo-Ibáñez T, del Carmen Ordóñez M, Muñoz-Fernández S, Madero-Prado R, Martín-Mola E.
    Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
    [No Abstract] [Full Text] [Related]

  • 13. TNF inhibitors for ankylosing spondylitis in the real world.
    McVeigh CM, Bell AL, Cairns AP.
    Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
    [No Abstract] [Full Text] [Related]

  • 14. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
    Goncalves DP, Laurindo I, Scheinberg MA.
    J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
    [No Abstract] [Full Text] [Related]

  • 15. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P, Jamieson B, Hoffman R.
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A major subset of patients with ankylosing spondylitis followed up in tertiary clinical care require anti-tumour necrosis factor alpha biological treatments according to the current guidelines.
    Temel M, Atagündüz P, Direskeneli H.
    Ann Rheum Dis; 2005 Sep; 64(9):1383-4. PubMed ID: 16100352
    [No Abstract] [Full Text] [Related]

  • 18. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
    Genre F, Miranda-Filloy JA, López-Mejias R, Carnero-López B, Ochoa R, Rueda J, González-Juanatey C, Blanco R, Llorca J, González-Gay MA.
    Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
    [No Abstract] [Full Text] [Related]

  • 19. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
    Hermann J, Müller T, Yazdani-Biuki B, Aringer M, Herold M, Ebner W, Ofner P, Graninger W.
    Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.